GLP-1 Medications and Heart Health: What the SELECT Trial Means for Cardiovascular Patients

The conversation about GLP-1 medications shifted permanently with the SELECT trial. What started as a weight-loss drug story became a cardiovascular medicine story — and the implications for patients with heart disease risk factors are substantial.

The SELECT Trial: A Watershed Moment

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a landmark trial — 17,604 adults with established cardiovascular disease, BMI ≥27, and no diabetes, randomized to semaglutide 2.4mg or placebo over a median of 40 months.

The results:

• 20% reduction in the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke (MACE).
• 15% reduction in all-cause mortality (though not the primary endpoint).
• 18% reduction in heart failure events.
• Benefits emerged early — within the first 6 months — and were sustained throughout the trial.

What made SELECT groundbreaking wasn't just the magnitude of benefit but the population: these were patients without diabetes. Prior cardiovascular outcomes data for GLP-1s (LEADER, SUSTAIN-6) involved diabetic patients, making it unclear whether the cardiovascular benefit was mediated through glucose control or independent mechanisms.

SELECT answered that question: the cardiovascular benefit is independent of glycemic effects.

How GLP-1s Protect the Heart

The cardiovascular benefits of GLP-1 agonists appear to extend beyond weight loss and include direct vascular effects:

• Anti-inflammatory properties: GLP-1 receptor activation reduces C-reactive protein (CRP) and other inflammatory markers implicated in atherosclerosis. SELECT showed significant CRP reduction in the semaglutide group.
• Blood pressure reduction: Average systolic reductions of 3–5 mmHg, meaningful at a population level for cardiovascular event prevention.
• Lipid improvements: Reductions in triglycerides and modest LDL improvement.
• Endothelial function: Emerging evidence suggests GLP-1 receptor activation improves blood vessel function and reduces oxidative stress.
• Weight loss itself: Reduced mechanical stress on the heart, improved insulin sensitivity, and decreased visceral adiposity all contribute to cardiovascular risk reduction.

Heart Failure and GLP-1s

The STEP-HFpEF trial studied semaglutide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Results showed improvements in heart failure symptoms, exercise tolerance, and quality of life. While not yet a primary indication, this data suggests GLP-1 therapy may benefit a subset of heart failure patients — a population with historically few effective treatment options.

Who Should Discuss GLP-1 Therapy with Their Cardiologist

• Patients with established cardiovascular disease (prior heart attack, stroke, peripheral artery disease) and BMI ≥27
• Patients with multiple cardiovascular risk factors (hypertension, dyslipidemia, family history) and obesity
• Patients with heart failure with preserved ejection fraction and obesity
• Patients who need weight loss to reduce cardiac surgical risk or improve candidacy for procedures

Clinical Monitoring for Cardiac Patients

Patients using GLP-1 therapy for cardiovascular risk reduction should have:

• Blood pressure monitored closely (antihypertensive dose adjustment may be needed)
• Heart rate monitoring (semaglutide can increase resting heart rate by 1–4 bpm)
• Lipid panels at baseline, 3 months, and 6 months
• Inflammatory markers (CRP) if being tracked as part of cardiac risk assessment
• Coordination between prescribing provider and cardiologist for patients on complex cardiac regimens